Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered ...

Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation ...

In the year after the elimination of a waiver requirement to prescribe buprenorphine, the number of prescribers increased above the anticipated value, but the number of persons who received the ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β 0 /β 0, β 0 /β 0-like, or non–β 0 /β ...

Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats ...

Most moderate-to-late–preterm infants need nutritional support after birth pending a sufficient supply and intake of mother’s breast milk; however, evidence for the best strategy for nutrition ...

Dr. Jamie Aron (Emergency Medicine): A 27-year-old man was evaluated at this hospital because of leg weakness. The patient had been in his usual state of health until 3 days before the current ...

A 47-year-old man presented with 2-day history of weakness and fever. Laboratory studies showed pancytopenia. A bone marrow biopsy showed promyelocytes with abundant intracellular rods.

A 57-year-old woman presented with a 3-day history of shortness of breath and dizziness. Laboratory studies showed severe anemia with hemolysis, along with cellular abnormalities in peripheral blood.

This phase 2 trial showed that a single subcutaneous dose of L9LS at the highest dose tested (300 mg) provided protective efficacy of 69.9% against P. falciparum infection and 77.4% against ...

The autologous cellular therapy exagamglogene autotemcel is generated by editing an erythroid-specific enhancer of BCL11A. Could another site be edited unintentionally? This study gauged the ...